Cargando…

First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease

BACKGROUND: Comparative effects on physical activity of mono and dual bronchodilators remain unclear in patients with treatment-naïve chronic obstructive pulmonary disease (COPD). We sought to compare the changes in physical activity before and after tiotropium and tiotropium/olodaterol treatment in...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Koichiro, Uchida, Masaru, Kato, Go, Takamori, Ayako, Kinoshita, Takashi, Yoshida, Makoto, Tajiri, Ryo, Kojima, Keisuke, Inoue, Hiroshi, Kobayashi, Hiromi, Sadamatsu, Hironori, Tashiro, Hiroki, Tanaka, Masahide, Hayashi, Shinichiro, Kawaguchi, Atsushi, Kimura, Shinya, Sueoka-Aragane, Naoko, Kawayama, Tomotaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501469/
https://www.ncbi.nlm.nih.gov/pubmed/32982204
http://dx.doi.org/10.2147/COPD.S268905
_version_ 1783584032367312896
author Takahashi, Koichiro
Uchida, Masaru
Kato, Go
Takamori, Ayako
Kinoshita, Takashi
Yoshida, Makoto
Tajiri, Ryo
Kojima, Keisuke
Inoue, Hiroshi
Kobayashi, Hiromi
Sadamatsu, Hironori
Tashiro, Hiroki
Tanaka, Masahide
Hayashi, Shinichiro
Kawaguchi, Atsushi
Kimura, Shinya
Sueoka-Aragane, Naoko
Kawayama, Tomotaka
author_facet Takahashi, Koichiro
Uchida, Masaru
Kato, Go
Takamori, Ayako
Kinoshita, Takashi
Yoshida, Makoto
Tajiri, Ryo
Kojima, Keisuke
Inoue, Hiroshi
Kobayashi, Hiromi
Sadamatsu, Hironori
Tashiro, Hiroki
Tanaka, Masahide
Hayashi, Shinichiro
Kawaguchi, Atsushi
Kimura, Shinya
Sueoka-Aragane, Naoko
Kawayama, Tomotaka
author_sort Takahashi, Koichiro
collection PubMed
description BACKGROUND: Comparative effects on physical activity of mono and dual bronchodilators remain unclear in patients with treatment-naïve chronic obstructive pulmonary disease (COPD). We sought to compare the changes in physical activity before and after tiotropium and tiotropium/olodaterol treatment in treatment-naïve COPD patients. METHODS: A prospective, multicenter, randomized, open-labeled, and parallel interventional study was conducted. Eighty Japanese patients with treatment-naïve COPD were randomized to receive either tiotropium or tiotropium/olodaterol treatment for 12 weeks. Spirometry and dyspnea index were assessed, and COPD assessment test (CAT) and the 6-minute walk distance (6MWD) were conducted before and after treatment. Evaluation of physical activity was assessed by a triaxle accelerometer over a 2-week period before and after treatment. RESULTS: There were no differences in the mean age (69.8 vs 70.4 years), body mass index (BMI) (22.5 vs 22.6 kg/m(2)) and mean % forced expiratory volume in 1 second (%FEV1) at baseline (61.5 vs 62.6%) between the two groups. Changes in FEV1 (mean±standard error, 242.8±28.8 mL) and transient dyspnea index (TDI) (2.4±0.3 points) before and after tiotropium/olodaterol treatment were greater than with tiotropium treatment (104.1±31.9 mL, p<0.01 and 1.5±0.3, p=0.02, respectively). Changes in the duration of physical activity with 1.0–1.5 metabolic equivalents (METs) estimated in the sedentary position following tiotropium/olodaterol treatment (−38.7±14.7 min) tended to be reduced more than with tiotropium treatment (−4.6±10.6 min) (p=0.06), although those with ≥2.0 METs numerically increased with both treatments (+10.8±7.6 min for tiotropium/olodaterol vs +8.3±7.6 min for tiotropium, p=0.82). Tiotropium/olodaterol treatment reduced the duration of physical activity with 1.0–1.5 METs (regression coefficient, −43.6 [95% CI −84.1, −3.1], p=0.04) in a multiple regression model adjusted for cofounding factors such as age, FEV1, total CAT scores, 6MWD, and TDI. CONCLUSION: This is the first study to report the impact of dual bronchodilator on physical activity in treatment-naïve COPD patients of Japanese with low BMI.
format Online
Article
Text
id pubmed-7501469
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75014692020-09-24 First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease Takahashi, Koichiro Uchida, Masaru Kato, Go Takamori, Ayako Kinoshita, Takashi Yoshida, Makoto Tajiri, Ryo Kojima, Keisuke Inoue, Hiroshi Kobayashi, Hiromi Sadamatsu, Hironori Tashiro, Hiroki Tanaka, Masahide Hayashi, Shinichiro Kawaguchi, Atsushi Kimura, Shinya Sueoka-Aragane, Naoko Kawayama, Tomotaka Int J Chron Obstruct Pulmon Dis Original Research BACKGROUND: Comparative effects on physical activity of mono and dual bronchodilators remain unclear in patients with treatment-naïve chronic obstructive pulmonary disease (COPD). We sought to compare the changes in physical activity before and after tiotropium and tiotropium/olodaterol treatment in treatment-naïve COPD patients. METHODS: A prospective, multicenter, randomized, open-labeled, and parallel interventional study was conducted. Eighty Japanese patients with treatment-naïve COPD were randomized to receive either tiotropium or tiotropium/olodaterol treatment for 12 weeks. Spirometry and dyspnea index were assessed, and COPD assessment test (CAT) and the 6-minute walk distance (6MWD) were conducted before and after treatment. Evaluation of physical activity was assessed by a triaxle accelerometer over a 2-week period before and after treatment. RESULTS: There were no differences in the mean age (69.8 vs 70.4 years), body mass index (BMI) (22.5 vs 22.6 kg/m(2)) and mean % forced expiratory volume in 1 second (%FEV1) at baseline (61.5 vs 62.6%) between the two groups. Changes in FEV1 (mean±standard error, 242.8±28.8 mL) and transient dyspnea index (TDI) (2.4±0.3 points) before and after tiotropium/olodaterol treatment were greater than with tiotropium treatment (104.1±31.9 mL, p<0.01 and 1.5±0.3, p=0.02, respectively). Changes in the duration of physical activity with 1.0–1.5 metabolic equivalents (METs) estimated in the sedentary position following tiotropium/olodaterol treatment (−38.7±14.7 min) tended to be reduced more than with tiotropium treatment (−4.6±10.6 min) (p=0.06), although those with ≥2.0 METs numerically increased with both treatments (+10.8±7.6 min for tiotropium/olodaterol vs +8.3±7.6 min for tiotropium, p=0.82). Tiotropium/olodaterol treatment reduced the duration of physical activity with 1.0–1.5 METs (regression coefficient, −43.6 [95% CI −84.1, −3.1], p=0.04) in a multiple regression model adjusted for cofounding factors such as age, FEV1, total CAT scores, 6MWD, and TDI. CONCLUSION: This is the first study to report the impact of dual bronchodilator on physical activity in treatment-naïve COPD patients of Japanese with low BMI. Dove 2020-09-14 /pmc/articles/PMC7501469/ /pubmed/32982204 http://dx.doi.org/10.2147/COPD.S268905 Text en © 2020 Takahashi et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Takahashi, Koichiro
Uchida, Masaru
Kato, Go
Takamori, Ayako
Kinoshita, Takashi
Yoshida, Makoto
Tajiri, Ryo
Kojima, Keisuke
Inoue, Hiroshi
Kobayashi, Hiromi
Sadamatsu, Hironori
Tashiro, Hiroki
Tanaka, Masahide
Hayashi, Shinichiro
Kawaguchi, Atsushi
Kimura, Shinya
Sueoka-Aragane, Naoko
Kawayama, Tomotaka
First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease
title First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease
title_full First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease
title_fullStr First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease
title_full_unstemmed First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease
title_short First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease
title_sort first-line treatment with tiotropium/olodaterol improves physical activity in patients with treatment-naïve chronic obstructive pulmonary disease
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501469/
https://www.ncbi.nlm.nih.gov/pubmed/32982204
http://dx.doi.org/10.2147/COPD.S268905
work_keys_str_mv AT takahashikoichiro firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT uchidamasaru firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT katogo firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT takamoriayako firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT kinoshitatakashi firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT yoshidamakoto firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT tajiriryo firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT kojimakeisuke firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT inouehiroshi firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT kobayashihiromi firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT sadamatsuhironori firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT tashirohiroki firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT tanakamasahide firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT hayashishinichiro firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT kawaguchiatsushi firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT kimurashinya firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT sueokaaraganenaoko firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT kawayamatomotaka firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease
AT firstlinetreatmentwithtiotropiumolodaterolimprovesphysicalactivityinpatientswithtreatmentnaivechronicobstructivepulmonarydisease